Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Actavis Sells China JV to Zhejiang Chiral Medicine

publication date: Jan 28, 2014
Actavis, the global generic drug company, has agreed to sell its interest in its China JV, Actavis (Foshan) Pharmaceuticals, to Zhejiang Chiral Medicine Chemicals. Two weeks ago, Actavis said China was too risky and the business opportunity too uncertain (see story). According to the company, other countries presented a better risk-reward proposition, and Actavis had decided to pull out of China. However, now Actavis says it intends to continue commercial operations in China, working with “its preferred business partners.” The company did not explain the apparent contradiction. More details....

Stock Symbol: (NYSE: ACT)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital